What Happens When You Stop Finasteride or Minoxidil: What the Trials Measured

Who This Is For#

This guide is for you if:

• You take finasteride, dutasteride, minoxidil or spironolactone and want to know what happens after stopping
• You are planning a pregnancy and need to understand washout before talking to your prescriber
• You have a side effect and want to know what the label says reverses
• You have paused treatment and shedding has started
• You have heard that tapering softens the rebound

This guide is NOT for you if:

• You have not started treatment; read When to Start Hair Loss Treatment
• Your shedding began after starting a drug; see How to Stop Minoxidil Shedding Phase
• You want a head-to-head of the drugs; see Hair Loss Medications Compared
• Your loss is patchy, painful, scarred or sudden; see When to See a Dermatologist

Finasteride: What "Reversal of Effect" Means#

What the trials actually compared#

The trial most people picture, in which men came off finasteride and were followed while their hair returned to where it started, does not exist. Kaufman's trials randomized "1553 men (18 to 41 years of age)" to "oral finasteride 1 mg/d or placebo" [1], with extensions running "up to four 1-year, placebo-controlled extension studies" [2]. Finasteride gave "durable improvements in scalp hair over five years" while "treatment with placebo led to progressive hair loss" [2]. Those compare continued drug with continued placebo; neither includes a treated-then-withdrawn arm, and we could not locate a journal paper reporting one. The finasteride guide covers the on-treatment data.

Where the twelve-month figure comes from, and where the untreated line goes#

The source of record is the FDA-approved Propecia label: "Withdrawal of treatment leads to reversal of effect within 12 months" [9]. That is a ceiling, not a schedule; how soon the loss starts and how quickly the protection fades is not quantified in any source we could quote, so we do not put a number on it.

Baseline also moves. In the placebo arms, Kaufman found "a loss of 239 hairs from baseline (26.3% decline in hair density) measured in the target area at 5 years" [3], with "75% of placebo patients rated as worsened from baseline at 5 years" [3]. Finasteride holds you above that line. Stop, and the benefit unwinds; after that, the only trajectory the trials measured is the placebo one [3]. Whether someone who stops after years of treatment lands on that line, above it, or below it was never measured.

Minoxidil: What Happens to Regrowth Without the Drug#

The Olsen crossover ran onto the drug, not off it#

The early topical minoxidil trials are often cited as discontinuation data; they are the reverse. In Olsen's "12-month double-blind, controlled trial of 2% and 3% topical minoxidil" [4], "After 4 months of study, the placebo group was crossed over to 3% topical minoxidil" [4]. The placebo group went onto the drug, not off it. Its useful line is about the floor: "No subject had a net hair loss in the target area during the study" [4]. The long follow-up is a maintenance cohort; regrowth "tended to peak at 1 year with a slow decline in regrowth over subsequent years" [5], so some drift on treatment is expected.

The closest thing to a stopping study is a cutting-back study#

"Forty-one men with male pattern baldness completed 132 study weeks (2 years 9 months) with topical minoxidil" [6] on once- or twice-daily maintenance. There was "a greater mean loss in those patients following the once-daily versus twice-daily topical minoxidil regimen (p = 0.05)" [6], yet "No subject lost nonvellus target hair as compared with baseline" [6]. Less drug cost some gained hair, which points the way you would expect if stopping cost all of it, but it is not a stopping study. See Minoxidil Once Daily.

The label, and the month count we could not find#

The common claim that regrowth is lost within a few months of stopping has no quotable trial abstract behind it that we could find. The source we can cite is the OTC label: "continued use is necessary to increase and keep your hair regrowth, or hair loss will begin again" [11]. No month count appears there. For oral minoxidil, a pooled safety analysis pooled "14 studies including 442 patients" [13] and reports nothing about hair after stopping; expecting it to behave like topical is an inference, not a measurement. See the oral minoxidil review.

Back to Baseline, or Below It?#

What the data can and cannot say#

A common worry about stopping is ending up worse off than if you had never started.

Where a floor was reported, it held, though those men were still using the drug [4][6]. But a person who stops years after starting is compared with the untreated version of themselves, further along the placebo curve [3]. The trials do not show that you fall beneath that curve, and they do not show that you do not, because nobody measured it. The Treatment Evidence Explorer covers the on-treatment data.

Tapering, Half-Lives and Washout#

Tapering has no evidence behind it#

Tapering is often suggested informally and is the least supported option in the literature. Targeted searches for finasteride dose reduction before stopping and for gradual minoxidil discontinuation returned no clinical trials, so no study shows that stepping down changes the timing, severity or endpoint of the shedding. That is an absence of evidence, not evidence of harm, and no protocol can be recommended on data. The Olsen frequency data [6] describe long-term maintenance, not a bridge to zero.

Finasteride clears fast; its effect does not#

The label states "Mean terminal half-life is approximately 5-6 hours in men 18-60 years of age" [9]. The gap between a half-life of hours and "within 12 months" [9] is not explained in the label; the most likely reason is the hair cycle, since a follicle that loses protection still has to complete its current phase before the change is visible.

Dutasteride's long tail#

The Avodart label states: "The terminal elimination half-life of dutasteride is approximately 5 weeks at steady state" [10]. A pharmacokinetic paper gives a shorter figure, "28 days of washout is needed between treatments because of its half-life of 7-9 days" [7], but that figure was used to size a washout in a bioequivalence-design study [7], the pharmacology literature otherwise treats dutasteride as a drug "with Long Half-Life" [8], and the label's steady-state figure is the one that describes someone who has taken it for months or years [10]. For a long-term user the label figure applies, and it becomes an instruction: "Patients should not donate blood until 6 months after their last dose of AVODART" [10], "to prevent administration of dutasteride to a pregnant female transfusion recipient" [10]. See Dutasteride vs Finasteride.

When a Clinician May Raise Stopping#

None of this is a recommendation to stop; these are situations a prescriber may raise, and the decision sits with them rather than with a page.

Pregnancy planning#

Finasteride carries "Pregnancy Category X" and "is contraindicated for use in women who are or may become pregnant" [9], because it "may cause abnormalities of the external genitalia of a male fetus" [9]. The label adds that "Women should not handle crushed or broken PROPECIA tablets when they are pregnant or may potentially be pregnant" [9]. Dutasteride "is contraindicated in women who are pregnant" [10], "AVODART capsules should not be handled by women who are pregnant or may be pregnant" because "Dutasteride can be absorbed through the skin" [10], and its long half-life means the conversation needs to start early. Spironolactone "should not be used in pregnancy due to its teratogenic effects" [12], and "Continuous treatment is required to sustain the effect" [12], so a pause means an expected loss of benefit. The minoxidil sources retrieved for this guide had no pregnancy section, so we state no category; ask the prescriber. See the spironolactone guide.

Adverse effects#

The label separates two findings often blurred together. In a controlled study, "finasteride at 5 times the dosage of PROPECIA (5 mg daily) produced significant median decreases of approximately 0.5 mL (-25%) compared to placebo in ejaculate volume, but this was reversible after discontinuation of treatment" [9]. Post-marketing reports separately list "sexual dysfunction that continued after discontinuation of treatment" [9]. One is a measured, reversible change at a higher dose; the other is persistence reports; neither yields a probability. A prescriber can weigh a dose or formulation change or a different drug before anyone stops; those are decisions for the prescriber, not for a page. Topical reactions are covered in Minoxidil Side Effects.

Before a transplant#

A targeted search for perioperative discontinuation of finasteride or minoxidil around hair transplantation returned no trials. If a surgeon asks you to pause or continue, discuss the reasoning with them. See the transplant decision guide.

The Shedding Weeks and Telogen Effluvium#

Why the shed is not immediate, and what it is#

The event most people notice after stopping is a shed, and the mechanism suggests it will not be immediate. Tosi and colleagues describe drugs acting "by precipitating the follicles into premature rest (telogen effluvium)" [14], where "hair loss becomes evident 2 to 4 months after starting treatment" [14]. That review covers drugs that cause loss, not withdrawal of drugs that prevent it. If the same mechanism applies, follicles pushed into rest would shed when rest ends, which would place a shed months rather than days after stopping; no retrieved source measured this after finasteride or minoxidil withdrawal.

Telogen effluvium is "characterized by excessive shedding of hair" [15], and a recognized problem is "its distinction from androgenetic alopecia (AGA) with which it is often associated" [16]. That is the whole question after stopping: a synchronized shed settles; pattern loss keeps narrowing the hair. Repeated photographs in consistent light tell them apart; see the tracking guide, the Shedding Timeline Projector and the telogen effluvium guide.

When the shed is not the drug#

See a dermatologist without waiting if you have:

• Round, well-defined bald patches with normal skin between them
• Redness, scale, pain, burning or itching along with the loss
• Smooth, shiny areas where follicle openings seem to have gone
• Loss that came on within days rather than months
• Fever, weight change, fatigue or other symptoms of being unwell

Frequently Asked Questions#

Related Resources#

• Complete Guide to Finasteride for Hair Loss: on-treatment trial data
• Dutasteride vs Finasteride: why the washout differs
• Oral Minoxidil for Hair Loss: dosing and adverse effects
• Minoxidil Once Daily: the reduced-frequency data
• How Long Until Hair Loss Treatment Works?: the other direction
• Telogen Effluvium: the shedding mechanism
• Spironolactone for Hair Loss in Women: the pregnancy question
• When to See a Dermatologist: red flags